| Heidi L Swenson, LCSW | |
|
2201 N Broadwell Ave, Grand Island, NE 68803-2153 | |
| (308) 382-3660 | |
| (308) 389-5136 |
| Full Name | Heidi L Swenson |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 2201 N Broadwell Ave, Grand Island, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093952434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | 3101 (Nebraska) | Secondary |
| 1041C0700X | Social Worker - Clinical | 1211 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heidi L Swenson, LCSW 2201 N Broadwell Ave, Grand Island, NE 68803-2153 Ph: (308) 382-3660 | Heidi L Swenson, LCSW 2201 N Broadwell Ave, Grand Island, NE 68803-2153 Ph: (308) 382-3660 |
News Archive
A normal, predominant bacterial species of the healthy vaginal microbiota can be engineered for potential use as a novel protective agent against HIV-1 transmission in women, according to a new publication from scientists at Osel, Inc. and their collaborators.
As provisions of the ''Affordable Health Care for America Act'' continue to come into effect, there is a tremendous need for employers across the country to learn about its impact on their businesses and employees, according to the results of "Health Care Reform 360 degree," a new national study by Market Strategies International, the highly-regarded global market research and consulting firm.
ExonHit Therapeutics today announced that it has obtained the "Innovative Company" accreditation from OSEO (the French state innovation agency), in recognition of the company's cutting-edge innovations in its target sectors.
Boehringer Ingelheim, one of the world's leading pharmaceutical companies, announced recently the launch of the 'In Reach Africa' program, an initiative aimed at facilitating quality and innovative human and animal healthcare access across the African continent.
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.
› Verified 9 days ago